0.000USD0.000Pre-market 07/24, 09:30 (ET)
57.85BMarket Cap
38.23P/E TTM
Key Figures
877.080Open
927.080High
607.97KVolume
38.23P/E TTM
24.36P/E Dynamic
--Dividend TTM
0.97%Turnover Ratio
851.720Prev. Close
845.300Low
349.39MTurnover
69.45P/E Static
6.87P/B
0.00%Div Yield TTM
17.36%ROA
934.62052wk High
2.54Volume Ratio
833.04MNet Profit
62.54MShares
24.1978EPS TTM
0.47Beta
20.15%ROE
510.05552wk Low
9.60%Amplitude
90.43%Gross Margin
57.85BMarket Cap
-0.06Reward/Risk
1.62%Risk Rate
Currency: USD Updated: 2026-07-23 Key Insights
argenx SE's fundamentals are relatively stable, and its growth potential is good.Its valuation is considered fairly valued, ranking 89 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 1057.22.In the medium term, the stock price is expected to trend up.The company has shown average stock market performance over the past month, with weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
argenx SE Highlights
StrengthsRisks
argenx SE News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
26
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
argenx SE Info
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Ticker SymbolARGX
Companyargenx SE
CEOvan Hauwermeiren (Tim)
Websitehttps://www.argenx.com/
Shareholders
FAQs
What is the current price of argenx SE (ARGX)?
The current price of argenx SE (ARGX) is 925.05.
What is the symbol of argenx SE?
The ticker symbol of argenx SE is ARGX.
What is the 52-week high of argenx SE?
The 52-week high of argenx SE is 934.62.
What is the 52-week low of argenx SE?
The 52-week low of argenx SE is 510.06.
What is the market capitalization of argenx SE?
The market capitalization of argenx SE is 57.85B.
Is argenx SE (ARGX) currently rated as Buy, Hold, or Sell?
According to analysts, argenx SE (ARGX) has an overall rating of Buy, with a price target of 1057.22.
What is the Earnings Per Share (EPS TTM) of argenx SE (ARGX)?
The Earnings Per Share (EPS TTM) of argenx SE (ARGX) is 21.08.
